BRPI0310144A8 - vitreólise farmacológica - Google Patents

vitreólise farmacológica

Info

Publication number
BRPI0310144A8
BRPI0310144A8 BRPI0310144A BRPI0310144A BRPI0310144A8 BR PI0310144 A8 BRPI0310144 A8 BR PI0310144A8 BR PI0310144 A BRPI0310144 A BR PI0310144A BR PI0310144 A BRPI0310144 A BR PI0310144A BR PI0310144 A8 BRPI0310144 A8 BR PI0310144A8
Authority
BR
Brazil
Prior art keywords
eye
vitreous
reduce
disorder
plasmin
Prior art date
Application number
BRPI0310144A
Other languages
English (en)
Inventor
De Smet Marc
Pakola Steve
Original Assignee
Thromb X Nv
Thrombogenics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0310144(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thromb X Nv, Thrombogenics Nv filed Critical Thromb X Nv
Publication of BRPI0310144A8 publication Critical patent/BRPI0310144A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02005—Chondroitin AC lyase (4.2.2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02019—Chondroitin B lyase (4.2.2.19)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Insulating Materials (AREA)

Abstract

"vitreólise farmacológica". um método de tratamento ou prevenção de um distúrbio, ou uma complicação de um distúrbio, de um olho de um indivíduo compreendendo a promoção do contato de um humor vítreo e/ou aquoso com a composição compreendendo uma forma truncada a partir de plasmina compreendendo uma forma catalítica de plasmina compreendendo um domínio catalítico de plasmina (tpcd). tpcds incluem, mas não são limitadas a, miniplasmina, microplasmina e seus derivados e suas variações. os métodos da invenção podem ser usados para reduzir a viscosidade do vítreo, liquefazer o vítreo, induzir descolamento vítreo posterior, reduzir o sangue hemorrágico do olho, limpar ou reduzir materiais tóxicos ao olho, limpar ou reduzir substâncias estranhas intra-oculares do olho, aumentar a difusão de uma composição administrada a um olho, reduzir neovascularização extra-retinal e quaisquer uma de suas combinações. o método pode ser usado na ausência de, ou como um adjuvante para, vitrectomia.
BRPI0310144A 2002-12-06 2003-12-05 vitreólise farmacológica BRPI0310144A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228409.9A GB0228409D0 (en) 2002-12-06 2002-12-06 Pharmacological vitreolysis
PCT/US2003/038714 WO2004052228A2 (en) 2002-12-06 2003-12-05 Pharmacological vitreolysis

Publications (1)

Publication Number Publication Date
BRPI0310144A8 true BRPI0310144A8 (pt) 2018-04-24

Family

ID=9949140

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0317033-0A BR0317033A (pt) 2002-12-06 2003-12-05 Vitreólise farmacológica
BRPI0310144A BRPI0310144A8 (pt) 2002-12-06 2003-12-05 vitreólise farmacológica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0317033-0A BR0317033A (pt) 2002-12-06 2003-12-05 Vitreólise farmacológica

Country Status (24)

Country Link
US (11) US7547435B2 (pt)
EP (3) EP2327415B1 (pt)
JP (4) JP5426063B2 (pt)
CN (1) CN100577202C (pt)
AT (1) ATE534400T1 (pt)
AU (1) AU2003300821C1 (pt)
BE (1) BE2013C055I2 (pt)
BR (2) BR0317033A (pt)
CA (1) CA2508606C (pt)
CY (2) CY1112561T1 (pt)
DK (1) DK1581254T3 (pt)
ES (2) ES2377965T3 (pt)
FR (1) FR13C0052I2 (pt)
GB (1) GB0228409D0 (pt)
HU (1) HUS1300040I1 (pt)
IL (3) IL169008A (pt)
LU (1) LU92273I2 (pt)
MX (1) MXPA05006038A (pt)
NO (4) NO333837B1 (pt)
NZ (1) NZ541075A (pt)
PT (2) PT2327416T (pt)
SI (1) SI1581254T1 (pt)
WO (1) WO2004052228A2 (pt)
ZA (1) ZA200505193B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7152975B2 (en) * 2000-11-10 2006-12-26 Cooper Vision, Inc. Junctionless ophthalmic lenses and methods for making same
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN1961070A (zh) 2004-04-22 2007-05-09 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
JP4796787B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007005856A1 (en) * 2005-06-30 2007-01-11 Ista Pharmaceuticals, Inc. Use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment
US8231869B2 (en) * 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070134230A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
WO2007128526A2 (en) * 2006-05-04 2007-11-15 Fovea Pharmaceuticals Sa Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
JP5539896B2 (ja) * 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
WO2009093970A1 (en) * 2008-01-22 2009-07-30 Omnio Healer Ab Method of improving wound healing
JP2011526585A (ja) * 2008-03-31 2011-10-13 スカルセル テラピュティク 皮膚の老化の美容的処置法
WO2009149199A2 (en) * 2008-06-04 2009-12-10 Talecris Biotherapeutics, Inc. Composition, method and kit for preparing plasmin
PT2403865E (pt) 2009-03-03 2015-11-18 Grifols Therapeutics Inc Métodos de preparação de plasminogénio
US8858924B2 (en) 2009-03-26 2014-10-14 Warsaw Orthopedic, Inc. Compositions and methods for treatment of hemorrhage
KR20120050442A (ko) 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
US20120189609A1 (en) 2009-08-28 2012-07-26 Thrombogenics Nv Improvement to trabeculectomy
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
RU2435553C1 (ru) * 2010-03-10 2011-12-10 Арсений Александрович Кожухов Способ лечения центральных субретинальных кровоизлияний
EP2661493B1 (en) 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
CA2839735A1 (en) * 2011-06-17 2012-12-20 Yong-xin LI D-serine for the treatment of visual system disorders
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
RU2484795C2 (ru) * 2011-08-18 2013-06-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ индукции задней отслойки стекловидного тела с помощью миниплазмина
AU2012321082B2 (en) 2011-12-01 2015-03-12 Oxurion NV Improving trabeculectomy outcome
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
RU2014140116A (ru) 2012-04-24 2016-06-10 Тромбодженикс Н.В. Антитела против pdgf-c
EP2968476B1 (en) * 2013-03-14 2021-05-05 Wayne State University A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016054079A1 (en) 2014-09-29 2016-04-07 Zyomed Corp. Systems and methods for blood glucose and other analyte detection and measurement using collision computing
FR3034992A1 (fr) 2015-04-15 2016-10-21 Arcadophta Milieu plasmatique ex vivo autologue riche en plasmine et procede d'obtention
ES2982294T3 (es) 2015-12-18 2024-10-15 Talengen Int Ltd Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus
DK3395354T3 (da) 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
CN108463240A (zh) * 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
RU2619991C1 (ru) * 2016-02-18 2017-05-22 Павел Владимирович Лыскин Способ лечения витреомакулярного тракционного синдрома
WO2017153567A1 (en) 2016-03-10 2017-09-14 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
CN110198732A (zh) 2016-12-15 2019-09-03 泰伦基国际有限公司 一种促进胰岛素受体底物-2表达的方法
JP6766253B2 (ja) 2017-03-28 2020-10-07 森永乳業株式会社 新規ビフィドバクテリウム属細菌
RU2674926C1 (ru) * 2018-02-01 2018-12-13 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. Способ оценки эффективности витреолизиса помутнений стекловидного тела
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CN110361242B (zh) * 2019-08-14 2022-01-18 武汉赛维尔生物科技有限公司 一种用于眼球组织的固定液以及眼球组织制片的预处理方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN116716251A (zh) * 2023-06-20 2023-09-08 中国医学科学院北京协和医院 一种玻璃体样本的单细胞处理方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658972A (en) * 1900-04-09 1900-10-02 Interchangeable Brake Beam Company Brake-beam.
US2624691A (en) * 1946-04-22 1953-01-06 Parke Davis & Co Fibrinolysin derived from blood and methods of obtaining the same
DK98833C (da) 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
US3234106A (en) * 1962-12-03 1966-02-08 Cutter Lab Soluble, purified profibrinolysin and fibrinolysin and method of producing same
US3950513A (en) * 1965-12-03 1976-04-13 Novo Terapeutisk Laboratorium A/S Process of stabilizing therapeutically useful plasmin solutions
IT1194135B (it) 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US5288485A (en) 1989-08-31 1994-02-22 Kao Corporation Vasodilating agent
ZA912770B (en) * 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
US5288489A (en) * 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
WO1994001128A1 (en) * 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5304118A (en) * 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5866120A (en) * 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US5973779A (en) 1996-03-29 1999-10-26 Ansari; Rafat R. Fiber-optic imaging probe
US6207066B1 (en) * 1996-07-23 2001-03-27 Nuvue Technologies, L.L.C. Method for purification of a blood component
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5722428A (en) * 1996-10-29 1998-03-03 Washington University Method for producing a posterior vitreous detachment
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
DE69836858T2 (de) 1997-05-22 2007-09-06 Ista Pharmaceuticals, Inc., La Jolla Verwendung von hyaluronidase zur herstellung eines augenpräparats zur glasskörperverflüssigung bei der behandlung von augenerkrankungen
AU2521999A (en) 1998-02-04 1999-08-23 Desire Jose Collen Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6462071B1 (en) 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6899877B2 (en) * 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6733750B1 (en) * 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US6585972B2 (en) * 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US20040081643A1 (en) * 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
US7455962B1 (en) 1999-11-10 2008-11-25 Toudai Tlo. Ltd. Method for preparing cell fraction containing hemangioblasts
US6355243B1 (en) * 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
PT1297016E (pt) * 2000-05-12 2006-07-31 Vlaams Interuniv Inst Biotech Utilizacao de inibidores de factor de crescimento placentario para o tratamento da angiogenese patologica, da arteriogenese patologica, da inflamacao, da formacao de tumores e/ou das figas vasculares
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
EP1343903B1 (en) * 2000-12-21 2007-11-14 Thromb-X N.V. A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
US20020139378A1 (en) * 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
FI20011132A0 (fi) 2001-05-30 2001-05-30 Innovationsagentur Markkeri hematopoieettisten kantasolujen tunnistamiseen
US7776026B2 (en) * 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US6787135B2 (en) * 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
WO2004045558A2 (en) * 2002-11-18 2004-06-03 President And Fellows Of Harvard College Compositions and methods for treating thrombotic disorders
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
EP1581254A2 (en) 2005-10-05
SI1581254T1 (sl) 2012-05-31
EP2327415B1 (en) 2017-10-18
BR0317033A (pt) 2005-10-25
WO2004052228A3 (en) 2004-10-07
EP2327416A1 (en) 2011-06-01
PT2327416T (pt) 2019-07-04
US20090081187A1 (en) 2009-03-26
US8747842B2 (en) 2014-06-10
CA2508606A1 (en) 2004-06-24
LU92273I9 (pt) 2019-01-15
US20080050356A1 (en) 2008-02-28
JP5451533B2 (ja) 2014-03-26
NO2013016I2 (no) 2017-06-28
GB0228409D0 (en) 2003-01-08
US7547435B2 (en) 2009-06-16
JP2006518708A (ja) 2006-08-17
ES2731625T3 (es) 2019-11-18
US20110171190A1 (en) 2011-07-14
US20130195887A1 (en) 2013-08-01
JP5996026B2 (ja) 2016-09-21
US20130202613A1 (en) 2013-08-08
AU2003300821C1 (en) 2012-03-22
US20050118158A1 (en) 2005-06-02
US20080095753A1 (en) 2008-04-24
EP1581254B1 (en) 2011-11-23
ES2377965T3 (es) 2012-04-03
US20110300123A1 (en) 2011-12-08
EP1581254A4 (en) 2007-03-28
US20090074739A1 (en) 2009-03-19
NO343759B1 (no) 2019-06-03
US20150064161A1 (en) 2015-03-05
US8383105B2 (en) 2013-02-26
BE2013C055I2 (pt) 2023-03-07
US20130302304A1 (en) 2013-11-14
US8460655B2 (en) 2013-06-11
US9186394B2 (en) 2015-11-17
JP5426063B2 (ja) 2014-02-26
JP2010222369A (ja) 2010-10-07
IL202851A0 (en) 2011-07-31
CN100577202C (zh) 2010-01-06
JP2015131842A (ja) 2015-07-23
EP2327416B1 (en) 2019-05-01
HK1082419A1 (en) 2006-06-09
IL202851A (en) 2015-04-30
JP2013241448A (ja) 2013-12-05
NO20052988L (no) 2005-09-05
US9770494B2 (en) 2017-09-26
US7803368B2 (en) 2010-09-28
DK1581254T3 (da) 2012-02-27
NO20121169A1 (no) 2012-10-12
CY1112561T1 (el) 2015-11-04
EP2327415A1 (en) 2011-06-01
CN1738641A (zh) 2006-02-22
US7867489B2 (en) 2011-01-11
WO2004052228A2 (en) 2004-06-24
HUS1300040I1 (hu) 2013-08-15
AU2003300821A1 (en) 2004-06-30
NO20121170A1 (no) 2012-10-12
NO2013016I1 (no) 2013-11-19
MXPA05006038A (es) 2006-03-08
LU92273I2 (fr) 2013-10-29
NO333837B1 (no) 2013-09-30
IL213838A0 (en) 2011-07-31
FR13C0052I1 (pt) 2013-04-10
IL169008A (en) 2011-08-31
NO20052988D0 (no) 2005-06-17
CA2508606C (en) 2015-07-28
US8834869B2 (en) 2014-09-16
NZ541075A (en) 2008-02-29
JP5739487B2 (ja) 2015-06-24
FR13C0052I2 (fr) 2014-11-21
US7914783B2 (en) 2011-03-29
CY2013033I1 (el) 2015-11-04
CY2013033I2 (el) 2015-11-04
ATE534400T1 (de) 2011-12-15
ZA200505193B (en) 2007-08-29
PT1581254E (pt) 2012-02-06
AU2003300821B2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
BRPI0310144A8 (pt) vitreólise farmacológica
Wong et al. Microplasmin (ocriplasmin) in pediatric vitreoretinal surgery: update and review
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
BR0017050A (pt) Oxazolidinonas suebstituìdas e seu emprego na área da coagulação do sangue
JP2016065089A (ja) 眼および付属器組織の炎症を処置するための治療組成物
CN101658491B (zh) 一种治疗角膜碱烧伤的羊膜滴眼液
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
AR039511A1 (es) Agentes que regulan, inhiben, o modulan la actividad y/o la expresion del factor de crecimiento del tejido conjuntivo (ctgf) como unico medio para disminuir la presion intraocular y para tratar las retinopatias glaucomatosas/neuropatias opticas
BRPI0608152A2 (pt) formulações para tratamento ocular
WO2004019884A3 (en) Agents and methods for enhancing bone formation
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BR0116251A (pt) composição de lágrimas artificiais contendo uma combinação de três demulcentes
Varshney et al. Current trends in topical therapies for chronic rhinosinusitis: update and literature review
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
BR0315939A (pt) Métodos para tratar ou prevenir degeneração macular em um paciente e maculopatia relacionada com idade, neovascularização coroidal, descolamento do epitélio de pigmento ou atrofia de epitélio de pigmento retinal e composição farmacêutica
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
Spitzer et al. Sodium hyaluronate gels as a drug‐release system for corticosteroids: release kinetics and antiproliferative potential for glaucoma surgery
CN100381169C (zh) 复合胶原蛋白滴眼液
Klama‐Baryła et al. The use of biostatic human amnion and platelet‐rich plasma in topical treatment of toxic epidermal necrolysis—a case report
AR047139A1 (es) Uso de memantina para preparar una composicion farmaceutica para tratar una enfermedad o estado en donde la migracion o proliferacion de celulas gliales o epiteliales de pigmento retinal causa o contribuye a causar dicha enfermedad o estado
AR015164A1 (es) Nuevas 1-aril-3-heteroaril-tioureas sustituidas y 1-aril-3-heteroaril-isotioureas sustituidas como agentes antiateroscleroticos, su uso en la manufacturade un medicamento y composicion farmaceutica que las contiene
AR015494A1 (es) Composicion de brinzolamida para incrementar el flujo de sangre en el tejido optico y su uso para la manufactura de un medicamento.
Majcher et al. The role of the vitreous in retinal disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2055 DE 25 /05/ 2010.

B25A Requested transfer of rights approved

Owner name: THROMBOGENICS N.V. (BE)

Free format text: TRANSFERIDO POR INCORPORACAO DE: THROMB-X NV

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL